<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During maturation, the capacity of dendritic cells (DCs) to uptake and process antigens becomes diminished while the expression of MHC molecules and costimulatory molecules is up-regulated </plain></SENT>
<SENT sid="1" pm="."><plain>These phenotypic changes make DCs potent antigen presenting cells with the ability to initiate and modulate immune responses </plain></SENT>
<SENT sid="2" pm="."><plain>Recent findings have shown that DCs can mediate direct cytotoxicity toward <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we investigated the effect of monocyte derived DC (moDC) on <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic tumor</z:e> cells by assessing the uptake of [<z:chebi fb="36" ids="29309">methyl</z:chebi>-3H]<z:chebi fb="0" ids="17748">thymidine</z:chebi> (3H-TdR), JAM test (radiometric assay for DNA fragmentation) and <z:chebi fb="0" ids="50076">51Cr</z:chebi>-release assay </plain></SENT>
<SENT sid="4" pm="."><plain>We found that moDCs significantly inhibited the growth of 6 tumor cell lines and stimulated another 4 cell lines independently of the expression of Fas protein </plain></SENT>
<SENT sid="5" pm="."><plain>MoDCs also inhibited the proliferation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in transwell culture, including two cell lines that were driven to proliferate by direct contact with moDCs </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath>, but not cytolysis, was detected in <z:hpo ids='HP_0000001'>all</z:hpo> the cell lines inhibited by moDCs </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, no <z:chebi fb="0" ids="35610">cytostatic</z:chebi> or cytotoxic effect was detected on K562 cells (<z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>) and BY94 cells (<z:hpo ids='HP_0003745'>sporadic</z:hpo> Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="8" pm="."><plain>The inhibitory activity of moDCs on Fas-expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells fully persisted after the neutralization of FasL </plain></SENT>
<SENT sid="9" pm="."><plain>Accordingly, there was no detection of FasL protein or FasL <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in moDC </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that moDCs can mediate a direct anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity against <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic tumor</z:e> cells through cytostasis in absence of contact or through <z:mpath ids='MPATH_3'>apoptosis</z:mpath> without triggering the Fas/FasL pathway </plain></SENT>
</text></document>